Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT).

Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT).

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Belatacept (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms BENEFIT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 03 May 2017 Results (n=374) examining the DQB1* typed cohorts from the BENEFIT and BENEFIT-EXT studies and evaluating whether belatacept-treated patients have a lower rate of isotype switching, presented at the 2017 American Transplant Congress.
    • 03 May 2017 Results analysing the effect of belatacept and cyclosporine based immunosuppression on pre-existing donor specific antibody (DSA) levels by mean fluorescence intensity in patients enrolled to BENEFIT and BENEFIT-EXT, presented at the 2017 American Transplant Congress.
    • 28 Jan 2016 Long-term results (n=666) published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top